Company: PSTV
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-178940
Chunk: 3

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: S-1
Chunk 3
---
 Agreement (such shares, the “Additional Commitment Shares”), or any combination thereof. See “The Lincoln Park Transaction” for a description of the Purchase Agreement and “Selling Stockholder”
for additional information regarding Lincoln Park.

The selling stockholder may sell or otherwise dispose of the shares of common stock
described in this prospectus in a number of different ways and at varying prices. See “Plan of Distribution” for more information about how the selling stockholder may sell or otherwise dispose of the common stock being registered
pursuant to this prospectus. The selling stockholder is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”).

The selling stockholder will pay all brokerage fees and commissions and similar expenses in connection with any resale or disposition of the
shares of common stock described in this prospectus by the selling stockholder. We will pay the expenses incurred in registering under the Securities Act the offer and sale of the shares of common stock to which this prospectus relates by the
selling stockholder, including legal and accounting fees. See “Plan of Distribution”.

Our common stock is currently listed on
the Nasdaq Capital Market (“Nasdaq”) under the symbol “PSTV”. On August 8, 2025, the closing price of our common stock, as reported on Nasdaq, was $0.80 per share.

Investing in our securities involves a high degree of risk. These risks are described in the “ Risk Factors” section on page 4 of this prospectus. You should also consider the risk factors described or referred to in any documents incorporated by reference in this prospectus, and in any applicable prospectus supplement, before investing in these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 2025

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                                               |     | ii |
| PROSPECTUS SUMMARY                                                                  |     |  1 |
| THE OFFERING                                                                        |     |  2 |
| RISK FACTORS                                                                        |     |  4 |
| FORWARD-LOOKING STATEMENTS                                                          |     |  7 |
| THE LINCOLN PARK TRANSACTION                                                        |     |  8 |
| USE OF PROCEEDS                                                                     |